Wei-Ting Hwang.

Alfred L Click to read more about the treatment . Garfall, M.D., Marcela V. Maus, M.D., Ph.D., Wei-Ting Hwang, Ph.D., Simon F. Lacey, Ph.D., Yolanda D. Mahnke, Ph.D., J. Joseph Melenhorst, Ph.D., Zhaohui Zheng, M.S., Dan T. Vogl, M.D., Adam D. Cohen, M.D., Brendan M. Weiss, M.D., Karen Dengel, R.N., B.S.N., Naseem D.S. Kerr, M.P.H., Adam Bagg, M.D., Bruce L. Levine, Ph.D., Carl H. June, M.D., and Edward A. Stadtmauer, M.D.: Brief Record: Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma Transduction of autologous T cells to express CD19-particular chimeric antigen receptors is a promising immunotherapeutic approach for the treatment of B-cell cancers.

Study co-writer Marco Rossi of Pisa University in Italy pointed out that ‘skin malignant melanoma is a particularly aggressive cancer connected with quick blood vessel growth, which means early diagnosis is vital for a good prognosis. The current diagnostic tools of exam by doctors, followed by biopsy, inevitably leads to many unnecessary invasive excisions.’ The brand new test might ‘lead to a substantial decrease in the number of biopsies currently undertaken,’ Rossi said. Two melanoma experts in the United States were cautiously optimistic about the test, but said more research is needed. ‘The study as presented offers many limitations and therefore further research is essential before it could be found in clinical practice,’ said Dr.